Onconova Therapeutics raises $6.5M for pre-leukemia therapy
Newton, Pennsylvania, biotechnology company Onconova Therapeutics Inc. in has raised $6.5 million in equity for its small-molecule therapies that target cancer cells while protecting healthy cells. The company that is co-based in Lawrenceville, New Jersey, wants to raise $15 million. Its leading therapy, Estybon, treats myelodysplastic syndrome, which is an early form of leukemia. Founded in 1998, Onconova uses its proprietary medical chemistry library to discover and develop small-molecule therapies that are aimed at novel targets to treat cancer